Engineered immune cells take on lupus in early trial
NCT ID NCT07031713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune response. The main goals are to check safety and find the right dose, while also seeing if it can reduce lupus symptoms. Only 12 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Union Hospita
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Eye tests could spot silent vision damage in lupus patients
- Could a simple blood test predict lupus in children with ITP?
- Can an extra shot boost COVID protection in autoimmune patients?